Alvea is a biotechnology company dedicated to deploying medical countermeasures that fight infectious diseases. We are developing new vaccines against SARS-CoV-2 and its variants as step one in a plan to strengthen humanity against future biological threats.
Our mission /
To Build a Vaccine Platform for Pandemic Response as Global, Flexible, and Fast as the Pathogens we Face.
We’re a team of drug designers, clinical development experts, physicians, and operators dedicated to deploying novel medical countermeasures for use against pandemics.
We build simple, scalable, and shelf-stable medicines and prophylactics appropriate for use anywhere that humans call home.
The threat from new pathogens has never been greater. We need motivated, fast-moving people with a broad range of backgrounds and specialties.
If you think you’d be a good fit, or you want to hear more about opportunities at Alvea, please get in touch.
Latest News /
A Vaccine Developer Finds a Partner in Growth
with Neha Shah, Finance at Alvea. Alvea is tackling big and timely problems. The company launched in January 2022 and is building a vaccine platform for pandemic preparedness. Its first vaccine candidate is a shelf-stable, scalable, and affordable SARS-CoV-2 vaccine that’s tailored to the BA.2 (i.e., omicron) COVID-19 subvariant. Alvea’s vaccines are easier to store […]
Alvea Launches Scalable, Shelf- Stable DNA Vaccine Development against New SARS-CoV-2 Variants
Breakthrough DNA vaccine, Alveavax, enters pre-clinical testing for Omicron & BA.2 variants. CAMBRIDGE, Mass., Feb. 16, 2022 /PRNewswire/ — Alvea, a startup biotechnology company, today announced that it will begin to develop, test, and deliver DNA vaccines at scale to low and middle income countries with limited access to existing vaccine options. Alvea is a team of […]
Announcing Alvea — A Covid-19 Vaccine Project
We’ve had effective COVID vaccines for more than a year, but there are still countries where less than 10% of people have received a dose. Omicron has been spreading for almost three months, but pharma companies have only just started testing variant-specific shots. mRNA vaccines are highly effective, but they’re hard to manufacture and nearly […]